Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Obesity 7 Endometrial Neoplasms 5 Prostatic Neoplasms 2 Overweight 2 Endometrial Hyperplasia 2 Diabetes Mellitus 2 Breast Neoplasms 2 Weight Loss 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycystic Ovary Syndrome 1 Opioid-Related Disorders 1 Lymphoma, Follicular 1 Insulin Resistance 1 Hyperplasia 1 Colorectal Neoplasms 1

Interventions

Exercise 10 Diet 5 Caloric Restriction 5 Nutrition Assessment 4 Metformin 4 Octreotide 3 Megestrol Acetate 3 Cognitive Behavioral Therapy 3 anamorelin 2 Standard of Care 2 Olanzapine 2 Mirtazapine 2 Melatonin 2 Liraglutide 2 Eicosapentaenoic Acid 2 Diet, Carbohydrate-Restricted 2 Diet Therapy 2 sibutramine 1 remune 1 olanzapine-fluoxetine combination 1 lime 1 irinotecan sucrosofate 1 bermekimab 1 Weight Reduction Programs 1 Tirzepatide 1 TOPS 1 Surveys and Questionnaires 1 Sugars 1 Sampling Studies 1 Ritonavir 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Weight Loss × Tirzepatide × Clear all

NCT06518837 2026-01-21

FITWISE

Rutgers, The State University of New Jersey

Phase 2 Recruiting

Weight Loss

Data powered by HemOnc (CC BY 4.0) Colophon ⚡